Literature DB >> 27032930

Impact of depressive symptoms and hepatic encephalopathy on health-related quality of life in cirrhotic hepatitis C patients.

Katherine C Barboza1, Lilian M Salinas2, Farhad Sahebjam2, Arun B Jesudian3, Ilan L Weisberg4, Samuel H Sigal2.   

Abstract

Depression, common in chronic medical conditions, and hepatic encephalopathy (HE), a reversible neuropsychiatric syndrome due to liver dysfunction, are associated with impaired health-related quality of life (HRQOL) in cirrhosis and hepatitis C (HCV). This study investigated the impact of depression and HE on HRQOL in cirrhotic patients with HCV. A convenience sample of 43 ambulatory patients, with varying degrees of cirrhosis secondary to HCV, was prospectively enrolled in this study. Participants were assessed for any current depressive, fatigue, and daytime sleepiness symptoms and underwent a psychometric evaluation to determine the presence of HE symptoms. Participants reported current HRQOL on general health and liver disease-specific questionnaires. Diagnosis and current health status were confirmed via medical records. The associations between disease severity, depressive symptoms, HE, fatigue, and daytime sleepiness were measured. Predictors of HRQOL in this sample were determined. Depressive symptoms (70 %) and HE (77 %) were highly prevalent in this sample, with 58 % actively experiencing both conditions at the time of study participation. A significant positive association was found between depressive symptoms and HE severity (P = .05). Depressive symptoms were significantly associated with fatigue (P < .001), daytime sleepiness (P < .001), general HRQOL (P < .001), and disease-specific HRQOL (P < .001). HE was significantly associated with fatigue (P = .02), general HRQOL (P < .001), and disease-specific HRQOL (P < .001). Depressive symptoms and HE were significant predictors of reduced HRQOL (P < .001), with depressive symptoms alone accounting for 58.8 % of the variance. Depressive symptoms and HE accounted for 68.0 % of the variance. Findings suggest a possible pathophysiological link between depression and HE in cirrhosis, and potentially a wider-reaching benefit of treating minimal and overt HE than previously appreciated.

Entities:  

Keywords:  Cirrhosis; Depression; Fatigue; Health-Related Quality of Life; Hepatic Encephalopathy; Hepatitis C

Mesh:

Year:  2016        PMID: 27032930     DOI: 10.1007/s11011-016-9817-y

Source DB:  PubMed          Journal:  Metab Brain Dis        ISSN: 0885-7490            Impact factor:   3.584


  69 in total

1.  Hepatic encephalopathy in our genes?

Authors:  Jan Albrecht
Journal:  Ann Intern Med       Date:  2010-09-07       Impact factor: 25.391

2.  Validation of a fatigue impact score in primary biliary cirrhosis: towards a standard for clinical and trial use.

Authors:  M I Prince; O F James; N P Holland; D E Jones
Journal:  J Hepatol       Date:  2000-03       Impact factor: 25.083

3.  Health-related quality of life in patients with chronic hepatitis C and advanced fibrosis.

Authors:  Herbert L Bonkovsky; Kristin K Snow; Peter F Malet; Carla Back-Madruga; Robert J Fontana; Richard K Sterling; Clark C Kulig; Adrian M Di Bisceglie; Timothy R Morgan; Jules L Dienstag; Marc G Ghany; David R Gretch
Journal:  J Hepatol       Date:  2006-11-27       Impact factor: 25.083

4.  Major depression and suicide attempts in patients with liver disease in the United States.

Authors:  Yann Le Strat; Bernard Le Foll; Caroline Dubertret
Journal:  Liver Int       Date:  2014-06-23       Impact factor: 5.828

Review 5.  Comorbid depression and health-related quality of life in patients with coronary artery disease.

Authors:  Lesley Stafford; Michael Berk; Prasuna Reddy; Henry J Jackson
Journal:  J Psychosom Res       Date:  2007-04       Impact factor: 3.006

6.  Previous overt hepatic encephalopathy rather than minimal hepatic encephalopathy impairs health-related quality of life in cirrhotic patients.

Authors:  Federica Moscucci; Silvia Nardelli; Ilaria Pentassuglio; Chiara Pasquale; Lorenzo Ridola; Manuela Merli; Oliviero Riggio
Journal:  Liver Int       Date:  2011-08-15       Impact factor: 5.828

7.  A new method for measuring daytime sleepiness: the Epworth sleepiness scale.

Authors:  M W Johns
Journal:  Sleep       Date:  1991-12       Impact factor: 5.849

Review 8.  Review article: depression and the use of antidepressants in patients with chronic liver disease or liver transplantation.

Authors:  B H Mullish; M S Kabir; M R Thursz; A Dhar
Journal:  Aliment Pharmacol Ther       Date:  2014-09-01       Impact factor: 8.171

9.  Changes in mood states and biomarkers during peginterferon and ribavirin treatment of chronic hepatitis C.

Authors:  Robert J Fontana; Ziad Kronfol; Karen L Lindsay; Linas A Bieliauskas; Latha Padmanabhan; Carla Back-Madruga; Anna S F Lok; Anne M Stoddard
Journal:  Am J Gastroenterol       Date:  2008-08-21       Impact factor: 10.864

Review 10.  Depression and risk of mortality in people with diabetes mellitus: a systematic review and meta-analysis.

Authors:  Fleur E P van Dooren; Giesje Nefs; Miranda T Schram; Frans R J Verhey; Johan Denollet; François Pouwer
Journal:  PLoS One       Date:  2013-03-05       Impact factor: 3.240

View more
  9 in total

1.  Significant Decrease in the Prevalence of Anxiety and Depression after Hepatitis C Eradication.

Authors:  Justyna Slonka; Damian Piotrowski; Ewa Janczewska; Arkadiusz Pisula; Joanna Musialik; Jerzy Jaroszewicz
Journal:  J Clin Med       Date:  2022-05-28       Impact factor: 4.964

2.  Mindfulness-Based Stress Reduction Therapy Improves Patient and Caregiver-Reported Outcomes in Cirrhosis.

Authors:  Jasmohan S Bajaj; Michael Ellwood; Timothy Ainger; Thomas Burroughs; Andrew Fagan; Edith A Gavis; Douglas M Heuman; Michael Fuchs; Binu John; James B Wade
Journal:  Clin Transl Gastroenterol       Date:  2017-07-27       Impact factor: 4.488

3.  A Survey on the Prevalence of Depression in Blood Donors with Hepatitis C in Shiraz.

Authors:  Leila Kasraian; Neda Negarestani; Mohammad Hossein Karimi; Sahar Dehbidi
Journal:  Hepat Mon       Date:  2016-11-06       Impact factor: 0.660

4.  Systematic Review of the Economic Burden of Overt Hepatic Encephalopathy and Pharmacoeconomic Impact of Rifaximin.

Authors:  Guy Neff; Woodie Zachry
Journal:  Pharmacoeconomics       Date:  2018-07       Impact factor: 4.981

5.  Overt Hepatic Encephalopathy Experienced by Individuals With Cirrhosis: A Qualitative Interview Study.

Authors:  Lea Ladegaard Grønkjær; Thomas Hoppe Sehstedt; Annelise Norlyk; Hendrik Vilstrup
Journal:  Gastroenterol Nurs       Date:  2018 Nov/Dec       Impact factor: 0.978

6.  A scoping review to identify and map the multidimensional domains of pain in adults with advanced liver disease.

Authors:  Franklin F Gorospe; Laura Istanboulian; Martine Puts; David Wong; Elizabeth Lee; Craig M Dale
Journal:  Can J Pain       Date:  2020-09-15

7.  Abnormal corpus callosum induced by overt hepatic encephalopathy impairs interhemispheric functional coordination in cirrhosis patients.

Authors:  Yangying Kuang; Xiaojia Wu; Hua Lai; Zhigang Wang; Qiang Lei; Weijia Zhong; Ya Yang; Chen Deng; Zhiming Zhou
Journal:  Ann Transl Med       Date:  2021-10

8.  Pre-Transplant Depression Is Associated with Length of Hospitalization, Discharge Disposition, and Survival after Liver Transplantation.

Authors:  Shari S Rogal; Gautham Mankaney; Viyan Udawatta; Matthew Chinman; Chester B Good; Susan Zickmund; Klaus Bielefeldt; Alexis Chidi; Naudia Jonassaint; Alison Jazwinski; Obaid Shaikh; Christopher Hughes; Paulo Fontes; Abhinav Humar; Andrea DiMartini
Journal:  PLoS One       Date:  2016-11-07       Impact factor: 3.240

Review 9.  Impact of Hepatic Encephalopathy in Cirrhosis on Quality-of-Life Issues.

Authors:  Sara Montagnese; Jasmohan S Bajaj
Journal:  Drugs       Date:  2019-02       Impact factor: 9.546

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.